LEADER 01289nam 2200277la 450 001 9910481517403321 005 20210618142906.0 035 $a(UK-CbPIL)2090349944 035 $a(CKB)5500000000105336 035 $a(EXLCZ)995500000000105336 100 $a20210618d1552 uy | 101 0 $alat 135 $aurcn||||a|bb| 200 10$aM. Tullij Ciceronis Epistolae familiares. Pauli Manutij Scholia, quibus harum epistolarum locos complures ab alijs propter obscuritatem aut omissos, aut minus recte explanatos, partim interpretatur, partim corrigit$b[electronic resource] 210 $aVenice $cPaolo Manuzio, 1512-1574$d1552 215 $aOnline resource (2 pt. (267, [5]; [40] c.), 8°.) 300 $aReproduction of original in Biblioteca Nazionale Centrale di Firenze. 700 $aCicero$b Marcus Tullius$082411 701 $aManuzio$b Paolo$f1512-1574.$0327584 701 $aManuzio$b Aldo$f1449 or 1450-1515.$0743643 801 0$bUk-CbPIL 801 1$bUk-CbPIL 906 $aBOOK 912 $a9910481517403321 996 $aM. Tullij Ciceronis Epistolae familiares. Pauli Manutij Scholia, quibus harum epistolarum locos complures ab alijs propter obscuritatem aut omissos, aut minus recte explanatos, partim interpretatur, partim corrigit$92213228 997 $aUNINA LEADER 10640nam 22004573 450 001 9910855364403321 005 20240505090318.0 010 $a3-031-52581-7 035 $a(MiAaPQ)EBC31318910 035 $a(Au-PeEL)EBL31318910 035 $a(CKB)31889898300041 035 $a(EXLCZ)9931889898300041 100 $a20240505d2024 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRaynaud's Phenomenon $eFrom Pathogenesis to Management 205 $a2nd ed. 210 1$aCham :$cSpringer,$d2024. 210 4$d©2024. 215 $a1 online resource (444 pages) 311 $a3-031-52580-9 327 $aIntro -- Foreword by Antony Rosen -- Foreword by Dame Carol Black -- Preface -- Acknowledgments -- Contents -- List of Contributors -- 1: Historical Perspective of Raynaud's Phenomenon -- Milestones -- Pathogenetic Mechanisms -- Epidemiology -- Diagnosis -- Treatment -- Conclusion -- References -- 2: Definition, Nomenclature, and Diagnostic Criteria -- Definition -- Nomenclature -- Other Terms Used to Describer Digital Ischemia -- Criteria for Classification -- Diagnostic Criteria -- Summary -- References -- 3: Epidemiology of Raynaud's Phenomenon -- Primary RP -- Incidence and Prevalence of Primary RP -- Risk Factors for Primary RP -- Age -- Female Sex -- Low Body Weight -- Environmental Factors -- Genetic Factors for Primary and Secondary RP -- Secondary RP -- Incidence and Prevalence of Secondary RP -- Aetiology of Secondary RP -- Systemic Sclerosis -- Other Autoimmune Diseases -- Other Systemic Diseases -- Neurologic Diseases -- Drugs (Chap. 9) -- Occupational Exposure to Vibration (Chap. 9) -- Risk and Prognostic Factors for Progression to Systemic Disease -- RP as Risk Factor for Digital Ischemia, Gangrene, and Auto-Amputation -- RP as Risk Factor for Other Organ Manifestations -- Function, Morbidity, and Mortality -- Expert Opinion -- References -- 4: The Normal Structure and Function of the Cutaneous Vascular System -- General Aspects of Vascular Systems -- Specialization of the Cutaneous Circulation -- Cold-Induced Cutaneous Constriction -- Responses to Cooling -- Mechanisms Responsible for Cooling-Induced Constriction -- Transient Receptor Potential Channels and Efferent Pathways Responsible for Cooling-Induced Constriction -- Cooling-Induced Cutaneous Vasodilatation -- Thermogenesis -- Gender-Dependent Changes in Cold-Induced Vasoconstriction -- Expert Opinion: Some Missing Links -- References. 327 $a5: A Mechanistic Approach to Understanding and Preventing the Vasculopathy of Raynaud's Phenomenon -- Mechanisms Underlying Increased Cold-Induced Vasoconstriction in RP -- Sympathetic Adrenergic Activity -- Endothelial Dilator Function -- Thermogenesis -- The Color Changes of PRP -- Mechanisms Responsible for the Functional and Structural Changes in the SSc Microvasculature -- Assessing Blood Flow in RP and SSc -- New Approaches to Treating the Vasculopathy of RP -- Countering RP Vasopasm -- Countering the SSc Vasculopathy -- References -- 6: Practical Approach to the Patient with Raynaud's Phenomenon: Primary Versus Secondary Raynaud's Phenomenon -- Introduction -- Case History -- Diagnosis of RP: Primary Versus Secondary RP -- History -- Examination -- Investigations -- Assessment of Severity of RP -- History -- Examination -- Investigations -- Management of RP -- Patient Education/General Measures -- Drug Treatment -- Surgical Treatment -- Transition from Primary to Secondary RP -- Expert Opinion -- References -- 7: Raynaud's Phenomenon in the Pediatric Age -- Introduction -- Epidemiology Including Secondary Causes -- Clinical Features -- History -- Examination -- Investigations -- Nailfold Capillaroscopy in Children -- Other Imaging Techniques -- Clinical Cases -- Case 1 -- Case 2 -- Predictors of Progression to CTD -- Differential Diagnosis -- Cervical Ribs -- Management -- General Measures -- Pharmacological Measures -- Expert Opinion -- References -- 8: Secondary Raynaud's Phenomenon: Focus on Rheumatic Diseases -- Introduction -- Individual Conditions Associated with Secondary RP -- Systemic Sclerosis (Scleroderma -- SSc) -- Systemic Lupus Erythematosus (SLE) -- Idiopathic Inflammatory Myopathy (IIM) -- Mixed Connective Tissue Disease (MCTD) -- Sjögren's Syndrome -- Rheumatoid Arthritis -- Undifferentiated Connective Tissue Disease (UCTD). 327 $aCOVID-19 -- Other Causes of Secondary RP: Vasculitis, Behcet's Syndrome, Thromboangiitis Obliterans, Antiphospholipid Syndrome (See Also Chap. 10) -- Vasculitis -- Behcet's Syndrome -- Thromboangiitis Obliterans -- Antiphospholipid Syndrome -- Management Principles -- Supportive Measures -- Combination Vasodilator Therapy -- Role for Surgical Intervention (See Chap. 20) -- Management of Vascular Co-morbidity -- Expert Opinion -- References -- 9: Other Secondary Causes -- Introduction -- Carpal Tunnel -- Introduction -- The Association Between Idiopathic Carpal Tunnel Syndrome and Raynaud's Phenomenon -- Carpal Tunnel Syndrome Secondary to Systemic Sclerosis -- Expert Opinion -- Drug and Toxins -- Introduction -- Immunosuppressive Agents -- Cyclosporine A -- Interferons -- Chemotherapeutic Agents -- Bleomycin, Vinblastine, Cisplatin and Other Agents -- Drugs Used in the Treatment of Hypertension -- Beta-Blockers -- Clonidine -- Drugs Used in the Treatment of Anxiety and Headache Syndromes, and Amphetamines -- Ergots -- Methysergide -- Drugs Targeting Calcitonin Gene-Related Peptide -- CNS Stimulants Used to Treat ADHD -- Toxins (Including Occupational Exposure) -- Cocaine and Cannabis -- Vinyl Chloride -- Expert Opinion -- Metabolic -- Introduction -- Thyroid Disorders -- Neuroendocrine Tumours: Carcinoid and Phaeochromocytoma -- POEMS Syndrome -- Expert Opinion -- Haematological -- Abnormal Cellular Components -- Polycythaemia and Thrombocythaemia -- Polycythaemia and Thrombocythaemia Due to Myeloproliferative Neoplasms -- Abnormal Blood Components -- Paraproteinaemia -- Cryoglobulins -- Cryofibrinogenaemia -- Cold Agglutinin Disease -- Coagulopathy -- Inherited Thrombophilias -- Expert Opinion -- Malignancy -- Solid Tumours -- Leukaemia, Lymphoma and Others -- Paraneoplastic Raynaud's Phenomenon and Digital Ischaemia. 327 $aRaynaud's Phenomenon Secondary to Localised Radiotherapy -- Expert Opinion -- Trauma -- Vibration Exposure -- Mechanical Percussive Injury, Palmar Trauma and the Hypothenar Hammer Syndrome -- Expert Opinion -- Conclusion -- References -- 10: Raynaud's Mimics -- Acrocyanosis -- Primary Pernio/Chilblains -- Chilblain Lupus -- Cold Hypersensitivity of the Hands and Feet -- Cold Injuries: Frostbite and Nonfreezing Cold Injury -- Thromboangiitis Obliterans (Buerger Disease) -- Livedo Reticularis and Racemosa -- Description -- Erythromelalgia -- Description -- Thoracic Outlet Syndrome -- Etiology -- Arterial or Venous TOS -- Management -- Neurogenic TOS -- Venous TOS -- Arterial TOS -- Complex Regional Pain Syndrome (CRPS) -- Description -- Etiology -- Evidence That CRPS Presents at Raynaud's -- Diagnosis -- Management -- References -- 11: Systemic Vasospasm -- Introduction -- Systemic Vasospasm in Systemic Sclerosis -- Coronary Perfusion -- Renal Vascular Bed and Scleroderma Renal Crisis -- Pulmonary Artery Vasospasm as a Contributor to Pulmonary Hypertension -- Vasospasm in Other Vascular Beds -- Scleroderma and Pregnancy -- Coexistence of Disorders of Abnormal Vascular Reactivity -- Migraine and Raynaud -- Migraines as a Disorder of Vasoreactivity? -- Vasospastic and Microvascular Angina -- Expert Opinion -- References -- 12: Nailfold Capillaroscopy -- Introduction -- Capillaroscopy: From the Beginning Up to Now -- Nailfold Capillaroscopy: Methods -- What Is Nailfold Capillary Microscopy (Capillaroscopy)? -- How to Perform Capillaroscopy -- Techniques: Devices for Daily Clinical Practice and Research Setting -- Number of Fingers to be Studied -- Interpretation -- EULAR and SCTC Consensus-Based Description and Interpretation of Capillaroscopy -- Qualitative Assessment -- (Semi)-Quantitative Assessment. 327 $aInvestigation of a Patient with RP: Role of Capillaroscopy -- Early Distinction Between a Primary and Secondary RP Due to SSc -- What Is Normal in Primary RP? -- What Are Pathognomonic Abnormalities in Patients with RP Due to SSc? -- The Fast Track Algorithm: A Fast Simple and Reliable Algorithm to Distinguish a "Scleroderma-Pattern" from a "Non-scleroderma" Pattern -- What Capillaroscopic Images Do We Find in Patients with RP and CTD Other Than SSc and Scleroderma Spectrum Diseases? -- "Early" Diagnosis of SSc -- How Often Should Capillaroscopy Be Performed in a Patient with RP? -- Relationship Between Altered Peripheral Blood Flow and Altered Capillaroscopy in Secondary RP -- Expert Opinion -- Conclusion -- References -- 13: Autoantibodies in Raynaud's Phenomenon -- Introduction -- Methods of Autoantibody Detection -- Indirect Immunofluorescence -- Enzyme Linked Immunosorbent Assay -- Immunoblotting -- Immunoprecipitation -- Autoantibodies and Raynaud's Phenomenon Associated with Autoimmune Rheumatic Disease -- Systemic Sclerosis -- Mixed Connective Tissue Disease -- Myositis -- Systemic Lupus Erythematosus -- Primary Sjogren's Syndrome -- Vasculitis -- Antiphospholipid Syndrome -- Interstitial Pneumonia with Autoimmune Features -- Autoantibodies in the Pathogenesis of Raynaud's -- Evidence of Direct Pathogenicity -- Other Autoantibodies with Potential Pathogenic Function -- Conclusion -- Expert Opinion -- References -- 14: Angiography -- Dynamic Versus Static Arterial Lesion -- Evaluating the Raynaud's Phenomenon Patient -- Patients with RP Secondary to a Connective Tissue Disease -- Angiography -- Digital Subtraction Angiography -- Complications of DSA -- Magnetic Resonance Angiography (MRA) -- Computerized Tomography Angiography (CTA) -- Expert Opinion -- References -- 15: Laboratory Assessment of Raynaud's Phenomenon -- Introduction. 327 $aConsiderations When Undertaking Vascular Imaging Studies. 676 $a616.131 700 $aWigley$b Fredrick M$01737697 701 $aHerrick$b Ariane L$01737698 701 $aFlavahan$b Nicholas A$01737699 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910855364403321 996 $aRaynaud's Phenomenon$94159663 997 $aUNINA